DDO-2728

• CAT Number: I040220
• CAS Number: 3029515-97-4
• Molecular Formula: C28H17F3N4O7
• Molecular Weight: 578.45
• Purity: ≥95%
• Synonyms: [4-(trifluoromethyl)phenyl]methyl 4-[6-(2,6-dihydroxy-3-nitrobenzoyl)pyrazolo[1,5-a]pyrimidin-2-yl]benzoate
• InChI: InChI=1S/C28H17F3N4O7/c29-28(30,31)19-7-1-15(2-8-19)14-42-27(39)17-5-3-16(4-6-17)20-11-23-32-12-18(13-34(23)33-20)25(37)24-22(36)10-9-21(26(24)38)35(40)41/h1-13,36,38H,14H2
• InChIKey: VIQXHWIGOQADLR-UHFFFAOYSA-N
• SMILES: C1=CC(=CC=C1COC(=O)C2=CC=C(C=C2)C3=NN4C=C(C=NC4=C3)C(=O)C5=C(C=CC(=C5O)[N+](=O)[O-])O)C(F)(F)F

DDO-2728 (CAT: I040220) is a potent and selective ALKBH5 inhibitor (IC₅₀ = 2.97 μM) that enhances N⁶-methyladenosine (m⁶A) modification, promoting apoptosis and G1/M cell cycle arrest in leukemia cells. It significantly reduces TACC3 and c-Myc expression at both mRNA and protein levels. DDO-2728 exhibits dose-dependent antiproliferative effects in MOLM-13 and MV4−11 cells (IC₅₀ = 0.45 and 1.2 μM) with minimal toxicity in HEK293 and HUVECs. In vivo, it suppresses tumor growth in xenograft models with a favorable safety profile. DDO-2728 also demonstrates strong metabolic stability in human plasma and microsomes, supporting its potential in cancer epitranscriptomics research.